Hemp seed oil is a nutrient-dense carrier and ingredient derived from cannabis sativa seeds, containing zero cannabinoids but offering fatty acid profiles, protein, and micronutrients that enhance bioavailability and product stability. Despite its non-intoxicating profile, hemp seed oil remains central to cannabinoid delivery systems and formulation science.
MCT oil has become the preferred carrier medium for CBD products due to its superior bioavailability profile, rapid absorption, and compatibility with the cannabinoid delivery ecosystem. Understanding how medium-chain triglycerides enhance cannabinoid uptake is essential for consumers and manufacturers optimizing product efficacy.
The extraction method and final cannabinoid profile of hemp products fundamentally affect bioavailability, efficacy, and legal compliance. We break down full-spectrum, broad-spectrum, and isolate formulations with current research and regulatory context.
THCV is a rare cannabinoid structurally similar to THC but with distinct pharmacological effects, showing preliminary evidence for appetite suppression and metabolic support. Current research remains limited, and legal status varies significantly by jurisdiction.
CBC is a non-intoxicating phytocannabinoid with emerging evidence for anti-inflammatory and neuroprotective effects, though human clinical data remains limited. As a minor cannabinoid, it’s gaining attention in full-spectrum and isolate formulations, but regulatory clarity and dosage standardization lag behind CBD and THC.
Cannabinol (CBN) is a mildly psychoactive cannabinoid formed as THC degrades over time, showing emerging promise in sleep support and pain management with minimal intoxicating effects. Current research suggests CBN may work through CB1/CB2 and TRPV1 pathways, though human clinical evidence remains limited.
Cannabigerol (CBG) is a non-intoxicating phytocannabinoid that serves as a biosynthetic precursor to THC and CBD. Emerging research suggests CBG may have anti-inflammatory, neuroprotective, and antimicrobial properties, though human clinical evidence remains limited.
Delta-8-THC is a naturally occurring cannabinoid structurally similar to Delta-9-THC but with distinct pharmacological properties and a complex legal status. This profile examines its mechanism of action, emerging research, and practical considerations for consumers in California and beyond.
Delta-9-THC is the primary psychoactive cannabinoid in cannabis, activating CB1 and CB2 receptors to produce intoxication, pain relief, and appetite stimulation. This profile covers THC’s pharmacology, evidence-backed effects, legal status, and safety considerations for consumers and patients.
CBD is a non-intoxicating phytocannabinoid with preliminary evidence for anxiety, inflammation, and seizure management. This profile examines receptor mechanisms, clinical research, legal status, and practical considerations for consumers and healthcare providers.